AMG 479

DRUG16 trials

Sponsors

NantCell, Inc., Translational Research in Oncology, Dana-Farber Cancer Institute, NantBioScience, Inc., M.D. Anderson Cancer Center

Conditions

Adenocarcinoma of the PancreasAdvanced MalignancyAdvanced Solid TumorsAdvanced Squamous Non-Small Cell Lung CancerAskin's TumorsBRAF Mutated MelanomaBone MetastasesBreast Cancer

Phase 1

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

CompletedNCT00630552

NantCell, Inc.Adenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer, Pancreatic Cancer

Start: 2007-06-30End: 2012-04-30Updated: 2024-10-17

QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer

TerminatedNCT00791154

NantCell, Inc.Extensive-stage Small Cell Lung Cancer, Lung Cancer, Small Cell Lung Cancer +1

Start: 2008-12-02End: 2013-05-01Updated: 2024-08-23

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

TerminatedNCT00807612

NantCell, Inc.Advanced Squamous Non-Small Cell Lung Cancer

Start: 2009-01-31End: 2010-08-31Updated: 2024-09-25

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

TerminatedNCT00819169

NantCell, Inc.Colorectal Cancer, Locally Advanced, Metastatic Cancer +5

Start: 2009-01-16End: 2011-08-10Updated: 2024-08-20

QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors

CompletedNCT00974896

NantCell, Inc.Advanced Malignancy, Advanced Solid Tumors, Cancer +2

Start: 2006-12-31End: 2011-04-30Updated: 2016-10-27

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

WithdrawnNCT01479179

M.D. Anderson Cancer CenterBreast Cancer

Start: 2012-11-30Updated: 2016-10-26

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

TerminatedNCT01562899

PfizerBRAF Mutated Melanoma, Metastatic Pancreatic Adenocarcinoma

Start: 2012-08-27End: 2015-04-01Updated: 2020-12-10

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

TerminatedNCT01708161

Novartis PharmaceuticalsPIK3CA Amplified Advanced Solid Tumors, PIK3CA Mutated Advanced Solid Tumors

Start: 2012-11-27End: 2017-06-01Updated: 2018-09-13

Phase 2

QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors

CompletedNCT00563680

NantCell, Inc.Askin's Tumors, Desmoplastic Small Round Cell Tumors, Estraosseous Ewing's Tumor +4

Start: 2007-10-31End: 2012-08-31Updated: 2016-10-27

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

CompletedNCT00626106

NantCell, Inc.Breast Cancer, Breast Tumors, Metastatic Cancer

Start: 2008-03-27End: 2011-09-23Updated: 2024-09-19

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

TerminatedNCT00718523

Translational Research in OncologyOvarian Neoplasms

Start: 2009-01-31End: 2014-11-30Updated: 2016-01-12

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer

CompletedNCT00719212

Translational Research in OncologyOvarian Neoplasms

Start: 2009-01-31End: 2013-05-31Updated: 2016-01-11

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

CompletedNCT00813605

NantCell, Inc.Metastatic Colorectal Cancer

Start: 2009-03-31End: 2012-06-30Updated: 2016-10-27

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

CompletedNCT01024387

Dana-Farber Cancer InstituteCarcinoid Tumor, Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor

Start: 2010-03-31End: 2017-01-31Updated: 2018-03-08

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

TerminatedNCT01318642

NantBioScience, Inc.Adenocarcinoma of the Pancreas, Locally Advanced, Unresectable

Start: 2012-05-31End: 2012-12-03Updated: 2024-11-08

Phase 3

QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

CompletedNCT01231347

NantCell, Inc.Adenocarcinoma of the Pancreas, Advanced Malignancy, Advanced Solid Tumors +13

Start: 2011-04-07End: 2012-12-12Updated: 2024-07-16

Related Papers

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

2015-01-21134 citations

Abstract 3683: Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab

Cancer Research2014-10-01

A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial.

Journal of Clinical Oncology2014-05-207 citations

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

2013-02-13129 citations